Analysts Set CervoMed Inc. Target Price at $22.17

CervoMed stock receives 'Moderate Buy' rating from research firms

Feb. 27, 2026 at 11:24am

Got story updates? Submit your updates here. ›

Shares of CervoMed Inc. (NASDAQ:CRVO) have been given an average rating of 'Moderate Buy' by ten research firms currently covering the stock. The average 1-year price target among analysts is $22.17.

Why it matters

CervoMed is a biotechnology company focused on developing treatments for age-related neurological disorders, including Alzheimer's disease and dementia. The analysts' ratings and price targets provide insight into the market's outlook on the company's drug pipeline and future prospects.

The details

The ten research firms covering CervoMed have issued a range of ratings, including one sell, one hold, seven buy, and one strong buy recommendations. The average 1-year price target of $22.17 represents a potential upside of over 20% from the stock's current trading price.

  • CervoMed was founded in 2010 and is headquartered in Boston, Massachusetts.

The players

CervoMed Inc.

A biotechnology company engaged in the development and commercialization of treatments for age-related neurologic disorders, including its lead drug candidate neflamapimod.

Rhumbline Advisers

An institutional investor that owns 5,830 shares of CervoMed, representing a 35.5% increase in its position during the first quarter.

Marshall Wace LLP

An institutional investor that purchased a new position in CervoMed during the second quarter, acquiring 76,000 shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The analysts' ratings and price targets for CervoMed suggest the market sees potential in the company's drug pipeline targeting age-related neurological disorders, which are a growing area of focus in the biotechnology industry.